Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Meta Platforms (Facebook)
META
|
+$709M |
| 2 |
Amazon
AMZN
|
+$653M |
| 3 |
Tesla
TSLA
|
+$457M |
| 4 |
Exxon Mobil
XOM
|
+$450M |
| 5 |
Uber
UBER
|
+$382M |
Top Sells
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$520M |
| 2 |
Netflix
NFLX
|
+$476M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$377M |
| 5 |
Apple
AAPL
|
+$374M |
Sector Composition
| 1 | Technology | 19.76% |
| 2 | Healthcare | 17.68% |
| 3 | Consumer Discretionary | 13.1% |
| 4 | Industrials | 7.95% |
| 5 | Consumer Staples | 7.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3276
Immunic
IMUX
$84.1M
| $112K | ﹤0.01% |
74,806
-502,594
| -87% | -$752K |
|
3277
CareCloud
CCLD
$160M
| $111K | ﹤0.01% |
73,200
+12,600
| +21% | +$19.1K |
|
3278
Moleculin Biotech
MBRX
$11.4M
| $111K | ﹤0.01% |
8,640
+627
| +8% | +$8.06K |
|
3279
Monogram Orthopaedics
MGRM
$233M
| $111K | ﹤0.01% |
+32,300
| New | +$111K |
|
|
ARMN
3280
Aris Mining
ARMN
$1.97B
| $111K | ﹤0.01% |
33,634
| – | – |
|
3281
Alset
AEI
$146M
| $110K | ﹤0.01% |
106,366
+13,400
| +14% | +$13.9K |
|
|
BRNS
3282
Barinthus Biotherapeutics
BRNS
$46M
| $110K | ﹤0.01% |
29,699
+8,299
| +39% | +$30.7K |
|
3283
Paramount Gold Nevada
PZG
$73.6M
| $110K | ﹤0.01% |
294,500
+170,200
| +137% | +$63.6K |
|
3284
DURECT Corp
DRRX
$59.3M
| $110K | ﹤0.01% |
186,166
-106,500
| -36% | -$62.9K |
|
3285
Pluri
PLUR
$40.5M
| $110K | ﹤0.01% |
23,800
+4,062
| +21% | +$18.8K |
|
3286
Astria Therapeutics
ATXS
$442M
| $109K | ﹤0.01% |
14,200
+4,100
| +41% | +$31.5K |
|
|
TRVN
3287
DELISTED
Trevena, Inc.
TRVN
| $109K | ﹤0.01% |
6,062
-1,036
| -15% | -$18.6K |
|
3288
CEL-SCI Corp
CVM
$67.7M
| $108K | ﹤0.01% |
+1,323
| New | +$108K |
|
3289
VYNE Therapeutics
VYNE
$8.04M
| $108K | ﹤0.01% |
46,376
+20,400
| +79% | +$47.5K |
|
3290
Forte Biosciences
FBRX
$130M
| $107K | ﹤0.01% |
5,192
+116
| +2% | +$2.39K |
|
3291
Invivyd
IVVD
$258M
| $107K | ﹤0.01% |
27,200
-21,585
| -44% | -$84.9K |
|
3292
Q32 Bio
QTTB
$22.9M
| $106K | ﹤0.01% |
9,700
-300
| -3% | -$3.28K |
|
3293
Dominari Holdings
DOMH
$108M
| $105K | ﹤0.01% |
40,726
+1,400
| +4% | +$3.61K |
|
3294
Meihua International Medical Technologies
MHUA
$13.6M
| $105K | ﹤0.01% |
+70,964
| New | +$105K |
|
3295
Scilex Holding
SCLX
$176M
| $105K | ﹤0.01% |
1,469
+1,083
| +281% | +$77.4K |
|
3296
MicroSectors FANG & Innovation -3x Inverse Leveraged ETN
BERZ
$3.01M
| $102K | ﹤0.01% |
2,600
-1,270
| -33% | -$49.8K |
|
|
VIRX
3297
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $102K | ﹤0.01% |
178,899
+30,700
| +21% | +$17.5K |
|
3298
Cyngn
CYN
$38.4M
| $100K | ﹤0.01% |
+46
| New | +$100K |
|
3299
SOPHiA GENETICS
SOPH
$216M
| $100K | ﹤0.01% |
21,300
+1,400
| +7% | +$6.57K |
|
3300
United States Antimony
UAMY
$571M
| $100K | ﹤0.01% |
400,358
+39,036
| +11% | +$9.75K |
|